Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Sep 7:2010:bcr0420102871.
doi: 10.1136/bcr.04.2010.2871.

Clinical safety of 1500 mg oral naltrexone overdose

Affiliations
Review

Clinical safety of 1500 mg oral naltrexone overdose

Albert Stuart Reece. BMJ Case Rep. .

Abstract

This case represents a clinical overdose of the largest known dose of oral naltrexone, equivalent to the taking of a whole bottle of the oral naltrexone preparation. The patient's intention was to control craving for alcohol and opiates. The patient quickly settled with expectant management. As such it demonstrates that earlier concerns that have been voiced in this area, particularly relating to naltrexone-related hepatotoxicity and depression, may have been overstated, at least in the experience of this patient. This patient's course was marked only by gastric irritation, of which she had some history. As such the present profile provides case report evidence consistent with more robust views of the patient safety of naltrexone itself, and opposing more cautious views. Her polydrug craving was suppressed for a period of 2 weeks, which raises the important question of the mechanism of action of naltrexone's generalised suppression of refractory hedonic consumptive addictive behaviours.

PubMed Disclaimer

Conflict of interest statement

Competing interests None.

Similar articles

References

    1. Rea F, Bell JR, Young MR, et al. A randomised, controlled trial of low dose naltrexone for the treatment of opioid dependence. Drug Alcohol Depend 2004;75:79–88 - PubMed
    1. Bell JR, Young MR, Masterman SC, et al. A pilot study of naltrexone-accelerated detoxification in opioid dependence. Med J Aust 1999;171:26–30 - PubMed
    1. Degenhardt L, Gibson A, Mattick RP, et al. Depot naltrexone use for opioid dependence in Australia: large-scale use of an unregistered medication in the absence of data on safety and efficacy. Drug Alcohol Rev 2008;27:1–3 - PubMed
    1. Hall WD, Wodak A. Is naltrexone a cure for heroin dependence? Med J Aust 1999;171:9–10 - PubMed
    1. Digiusto E, Shakeshaft A, Ritter A, et al. Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD). Addiction 2004;99:450–60 - PubMed

MeSH terms